Key facts
- This page summarizes Jeff E. Knight's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Jul 2024, 17:35.
Jeff E. Knight - 15 Jul 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- CRNX
- Reported as of
- 15 Jul 2024
- Net transaction value
- -$895,884
- SEC form
- 4
- Accepted by SEC
- 17 Jul 2024, 17:35:34 UTC
- Prior SEC filing
- 28 Jun 2024
- Next SEC filing
- 26 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- Marc Wilson, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeff E. Knight filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 17 Jul 2024.
Change
- Previous filing in this sequence was filed on 28 Jun 2024.
- Current net transaction value: -$895,884.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- $419,626
- Shares
- +17,499
- Change %
- +33%
- Price
- $23.98
- Shares after
- 70,079
- Date
- 15 Jul 2024
- Ownership
- Direct
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- $57,798
- Shares
- +2,887
- Change %
- +4.1%
- Price
- $20.02
- Shares after
- 72,966
- Date
- 15 Jul 2024
- Ownership
- Direct
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- $111,693
- Shares
- +5,687
- Change %
- +7.8%
- Price
- $19.64
- Shares after
- 78,653
- Date
- 15 Jul 2024
- Ownership
- Direct
CRNX
transaction
Common Stock
Sale
- Transaction value
- $1,485,000
- Shares
- -27,000
- Change %
- -34%
- Price
- $55.00
- Shares after
- 51,653
- Date
- 15 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Stock option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -17,499
- Change %
- -13%
- Price
- $0.000000
- Shares after
- 112,501
- Date
- 15 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,499
- Exercise price
- $23.98
- Footnotes
- F2
CRNX
transaction
Derivative
Stock option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,887
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 20,213
- Date
- 15 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,887
- Exercise price
- $20.02
- Footnotes
- F3
CRNX
transaction
Derivative
Stock option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,687
- Change %
- -6.2%
- Price
- $0.000000
- Shares after
- 85,313
- Date
- 15 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,687
- Exercise price
- $19.64
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Footnote F3
1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Footnote F4
1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.